Skip to main content
SpringerLink
Log in

Failure to detect prostate cancer in the PSA era: comments on N Engl J Med 2003; 349: 215–224 and N Engl J Med 2003; 349: 335–342

  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thompson I, Goodman P, Tangen C, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224.

    Google Scholar 

  2. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM (2003) Effect of verification bias on screening for prostate cancer by measurement of prostate-speci.c antigen. N Engl J Med 349: 335-342.

    Google Scholar 

  3. Godley PA, Schell MJ (1999) Adjusted odds ratios under nondifferential misclassi.cation: application to prostate cancer. J Clin Epidemiol 52: 129-136.

    Google Scholar 

  4. Carroll P, Coley C, McLeod D, et al. (2001) Prostate-speci.c antigen best practice policy-part I: early detection and diagnosis of prostate cancer. Urol 57: 217-224.

    Google Scholar 

  5. Dvorak HF (2003) How tumors make bad blood vessels and stroma. Am J Pathol 162: 1747-1757.

    Google Scholar 

  6. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM (2002) Preoperative serum prostate speci.c antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate speci.c antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 167: 103-111.

    Google Scholar 

  7. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J (1999) Serum prostate-speci.c antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53: 581-589.

    Google Scholar 

  8. Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 167: 2435-2439.

    Google Scholar 

  9. Fleshner N, Klotz L (2002) Role of ‘saturation biopsy’ in the detection of prostate cancer among di.cult diagnostic cases. Urology 60: 93-97.

    Google Scholar 

  10. Stewart CS, Leibovich BC, Weaver AL, Lieber MM (2001) Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166: 86-91.

    Google Scholar 

  11. Scheck A (2001) #x2018;Extreme#x2019; prostate biopsies: too many or not enough? Urol Times. http://ut.adv100.com/urologytimes/article/ articleDetail.jsp?id=2500.

  12. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. J Am Med Assoc 273: 548-552.

    Google Scholar 

  13. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer Statistics. CA Cancer J Clin Med 53: 5-26.

    Google Scholar 

  14. Food and Drug Administration (1994) FDA approves test for prostate cancer. http://www.fda.gov/bbs/topics/ANSWERS/ANS00598. html

  15. DiGiuseppe JA, Sauvageot J, Epstein JI (1997) Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 21: 174-178.

    Google Scholar 

  16. White E (1986) The e.ect of misclassi.cation of disease status in follow-up studies: implications for selecting disease classi.cation criteria. Am J Epidemiol 124: 816-825.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Elizabeth A. Platz

  2. The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    Elizabeth A. Platz & Angelo M. De Marzo

  3. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    Elizabeth A. Platz & Angelo M. De Marzo

  4. The Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    Angelo M. De Marzo

  5. Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA, USA

    Edward Giovannucci

  6. The Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA

    Edward Giovannucci

Authors
  1. Elizabeth A. Platz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo M. De Marzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Giovannucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Platz, E.A., De Marzo, A.M. & Giovannucci, E. Failure to detect prostate cancer in the PSA era: comments on N Engl J Med 2003; 349: 215–224 and N Engl J Med 2003; 349: 335–342. Cancer Causes Control 15, 91–94 (2004). https://doi.org/10.1023/B:CACO.0000016580.49577.09

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CACO.0000016580.49577.09

Keywords

Search

Navigation